KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) Leases (2018 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Leases for 8 consecutive years, with $345.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 5.99% year-over-year to $345.0 million, compared with a TTM value of $345.0 million through Dec 2025, down 5.99%, and an annual FY2025 reading of $345.0 million, down 5.99% over the prior year.
  • Leases was $345.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from $342.0 million in the prior quarter.
  • Across five years, Leases topped out at $531.0 million in Q2 2021 and bottomed at $342.0 million in Q3 2025.
  • Average Leases over 5 years is $415.5 million, with a median of $412.0 million recorded in 2023.
  • The sharpest move saw Leases soared 585.14% in 2021, then fell 16.95% in 2022.
  • Year by year, Leases stood at $495.0 million in 2021, then decreased by 15.35% to $419.0 million in 2022, then decreased by 5.25% to $397.0 million in 2023, then fell by 7.56% to $367.0 million in 2024, then dropped by 5.99% to $345.0 million in 2025.
  • Business Quant data shows Leases for TEVA at $345.0 million in Q4 2025, $342.0 million in Q3 2025, and $358.0 million in Q2 2025.